FDA Authorizes Libre Duo: Continuous Glucose and Ketone Monitoring Explained
The FDA has authorized Libre Duo 10 Day for people aged 2 and older with...
Fatty Liver Disease and Diabetes: Heart Risk to Watch
Plain-language guide to fatty liver disease, diabetes, and cardiovascular risk, with screening questions, safety notes...
Evolocumab and Cardiovascular Risk in High-Risk Diabetes: What VESALIUS-CV Found
A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with...
Early Weight Loss After Type 2 Diabetes Diagnosis: What a Large UK Study Found
A large UK cohort linked 15% early weight loss after type 2 diabetes diagnosis with...
Early Type 1 Diabetes Screening in Children: What Families Should Know
Plain-language guide to early type 1 diabetes screening in children, autoantibodies, risk, follow-up, teplizumab context...
Diabetes Apps in 2026: How to Choose Safer Tools
Diabetes apps can track glucose, food, medicines, and reports. Learn how to choose safer tools...
Dexcom G7 Sensor Recall: Lot Numbers, Risks, and What to Do
Dexcom G7 sensor recall guide covering affected lots, stolen scrapped products, infection and no-reading risks...
CGM and Type 1 Diabetes Complications: What Adults Should Know
A nationwide Korean cohort study linked continuous glucose monitoring with lower rates of several serious...
Canagliflozin 100 mg vs 300 mg: What a New Kidney and Heart Outcomes Analysis Found
A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300...